Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia

Verena S. Hoffmann, Joerg Hasford, Michael Deininger, Jorge Cortes, Michele Baccarani, Rüdiger Hehlmann

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences